HTD Huntingdon Life

RNS Number:8101P
Huntingdon Life Sciences Group PLC
10 January 2002



       LSR DECLARES OFFER FOR HUNTINGDON UNCONDITIONAL IN ALL RESPECTS



On 16 October 2001, a recommended offer (the "Offer") was made by Life
Sciences Research, Inc. ("LSR") for the entire issued share capital of
Huntingdon Life Sciences Group plc ("Huntingdon"), as set out in the Offer
Document of that date.



LSR announces that as at 3.00 p.m. (London time), 10.00 a.m. (New York City
time) on 10 January 2002, it had received acceptances in respect of a total of
262,778,327 Huntingdon Shares, representing approximately 89.5 per cent. of
the existing issued ordinary share capital of Huntingdon.



LSR hereby declares that the Offer is now unconditional in all respects.  LSR
announces that the Initial Offer Period ended at 3.00 p.m. (London time),
10.00 a.m. (New York City time) on 10 January 2002.  All Huntingdon Securities
for which acceptances have been received, and not properly withdrawn, will be
exchanged for shares of LSR Voting Common Stock, subject to the terms of the
Offer and applicable securities laws.



LSR also announces the beginning of a Subsequent Offer Period which will
expire on 7 February  2002.  During the Subsequent Offer Period, the Offer
will remain open for acceptance, but withdrawal rights will not apply.



Cancellation of Listing



As announced on 21 December 2001 the ordinary shares of Huntingdon will have
their listing on the Official List and trading on the London Stock Exchange
plc cancelled with effect from 24 January 2002.



Additional Information



On 9 October 2001, LSR issued warrants to Stephens Group, Inc. to purchase an
aggregate of 704,424 shares of LSR Voting Common Stock at a purchase price of
US$1.50 per share.  In addition, subject to compliance with their fiduciary
duties, the Huntingdon Directors who will constitute the entire LSR Board once
the Offer becomes, or is declared, unconditional in all respects, intend to
submit a proposal at the next LSR stockholder meeting to issue warrants to
Focused Healthcare Partners LLC (a company connected with certain directors)
to purchase an aggregate of 410,914 shares of LSR Voting Common Stock at the
same purchase price.



The acceptances include all acceptances received from the Huntingdon Directors
that had irrevocably undertaken to accept the Offer.  Save as disclosed,
neither LSR, nor the director of LSR, nor, so far as LSR is aware, any person
deemed to be acting in concert with it, owns or controls any Huntingdon
Securities or has any option to acquire any Huntingdon Securities, or has
entered into any derivative referenced to securities of Huntingdon which
remain outstanding.



Words and expressions in this announcement have the same meaning as they have
in the Offer Document dated 16 October 2001.



The director of LSR accepts responsibility for the information contained in
this announcement. To the best of the knowledge and belief of the director of
LSR (who has taken all reasonable care to ensure such is the case), the
information contained herein for which he accepts responsibility is in
accordance with the facts and does not omit anything likely to affect the
import of such information.


This announcement does not constitute an offer of any securities for sale or
an offer or an invitation to purchase any securities.  HUNTINGDON
SECURITYHOLDERS SHOULD READ THE OFFER DOCUMENT CAREFULLY BEFORE MAKING A
DECISION CONCERNING THE OFFER.



HUNTINGDON securityholders SHOULD read the following documents AND ANY OTHER
RELEVANT DOCUMENTS regarding the offer (described above) WHICH HAVE BEEN FILED
WITH THE sec, because they will contain important information:



  * LSR's preliminary offer document, any supplement thereto, the final
    offer document and exchange offer materials.
  * LSR's Registration Statement on Form S-4 and Schedule TO, each as
    amended, containing or incorporating by reference such documents and other
    information.
  * Huntingdon's Solicitation/Recommendation on Schedule 14D-9, as amended.



When these and other documents are filed with the SEC, they may be obtained
free of charge through the SEC's website at http//www.sec.gov.  Interested
parties may read and copy any reports, statements and other information filed
by Huntingdon and LSR at the US SEC public reference rooms at 450 Fifth
Street, N.W., Washington, D.C. 20549 or at the Commission's other public
reference rooms in New York, New York and Chicago, Illinois.  Please call the
SEC at +1-(800)-732-0330 for further information on public reference rooms.
If you are a Huntingdon Securityholder you may also obtain free of charge each
of these documents (when available) from Huntingdon by directing your request
in writing to PO Box 353, Alconbury, Huntingdon, Cambridgeshire, PE28 4BR,
England.



Life Sciences Research, Inc. is incorporated in Maryland, US and has been
established solely for the purpose of making the Offer.



This announcement contains statements that may be forward-looking as defined
in the US's Private Litigation Reform Act of 1995.  These statements are based
largely on Huntingdon's expectations and are subject to a number of risks and
uncertainties, certain of which are beyond Huntingdon's control, as more fully
described in Huntingdon's Form 10-K for the year ended 31 December 2000, as
filed with the US Securities and Exchange Commission.

Huntingdon Life (LSE:HTD)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024

Huntingdon Life (LSE:HTD)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024